←
Francesco Claps4,359 posts
Francesco Claps avatar

Francesco Claps

@FraClaps

MD, PhD candidate @UniLeiden | Consultant Urological Surgeon @iov_irccs | Fellow @NKI_nl | Former fellow Fundaciòn IVO | @SIU_Italia Communications Office

◷ Joined December 2011▧ 22 Photos and videos
Mirrors of Medicine avatar
⟳ Francesco Claps retweeted
Mirrors of Medicine@mirrorsmed·Sep 8

Can we preserve more kidney function by changing how we approach the tumour? 🤖🫘 Article📰 mdpi.com/2077-0383/15/16/623… Comparative Analysis of Perioperative Outcomes, Complications, and Early Renal Function After No-Touch Adaptive Versus Conventional Robot-Assisted Partial Nephrectomy for Clinically Localized Renal Tumours This retrospective study of 387 patients compared no-touch adaptive 🆚 conventional robot-assisted partial nephrectomy for localized renal tumours. The no-touch approach was completed in 87.4% of evaluable cases and was associated with shorter hospitalization🏥 , fewer readmissions and complications, and better early renal function. At three months, adjusted eGFR was 5.4 mL/min/1.73 m² higher with no-touch surgery. Prospective multicentre studies are needed to confirm these findings and assess long-term clinical relevance. @GGiannarini , @fanfa92 , @FraClaps , @AbbinantiMaria , @antonioamodeo , @AlessandroCres

Post attachment
OncoAlert avatar
⟳ Francesco Claps retweeted
OncoAlert@OncoAlert·Jul 30

Three landmark studies. One network meta-analysis. Which perioperative strategy currently shows the strongest signal for improving survival in muscle-invasive bladder cancer? This analysis compares today's leading approaches and explores what the evidence can—and cannot—tell us. Article👉 buff.ly/sUECNO9 Comparative efficacy of perioperative systemic therapies for muscle-invasive bladder cancer: a network meta-analysis of randomized trials This network meta-analysis evaluated perioperative treatment strategies for muscle-invasive #BladderCancer using data from three randomised trials. Compared with gemcitabine–cisplatin, both enfortumab vedotin–pembrolizumab and gemcitabine–cisplatin plus durvalumab📈 improved overall survival, event-free survival, and pathological complete response, with enfortumab vedotin–pembrolizumab ranking highest across outcomes. Although based on indirect comparisons within a sparse network, these findings help contextualise emerging perioperative treatment options and inform clinical decision-making. @albisinnidoc
@andreamari08
@FraClaps
@RobertoContieri
@agallioli
@DavDandrea
@E_Laukhtina
@wojciechpiotrk1
@elijeandin
@Luca_Afferi
@f_delgiudice
@UroMoschini
@LAUrology_NL
@Anto_cigliola
@CMercinelli
@MatteoSantoniMD
@BenjaminPradere
@AndreaNecchi Pinging faculty @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @AlbigesL @cdanicas @amerseburger @sonpavde @DrDanielHeng @declangmurphy @seanmmcbride @HHammersMD @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @scocmem @ravikanesvaran @AmandaNizamMD @drenriquegrande @BraunMDPhD @EfstathiouEleni @nataliagandur @crisbergerot

Post attachment
Markus Eckstein avatar
⟳ Francesco Claps retweeted
Markus Eckstein@Markuseckstein3·Jun 4

🧵 “Quo Vadis” #UroOncology & #ADC sequencing? A critical moment for our field! 🎯 #ASCO26 Exciting biomarker data from JAVELIN Bladder100 is reshaping how we think about ADC selection 🔬 ✅ NECTIN4 & HER2 = NOT prognostic for platinum chemo + avelumab maintenance 💡 BUT low NECTIN4 RNA → numerically prolonged OS (~30mo) with avelumab ⚠️ YET low NECTIN4 tumors = LESS favorable outcomes on EV-P & DVP 👉 Same marker. Opposite signals depending on treatment context — THIS is exactly why biomarker-driven ADC selection is no longer optional. It’s essential for properly treating patients with mUC and MIBC in the future as more and more drugs will come up! 🌏 China is already showing us the way — the ONLY country right now with 2 anti-HER2 & 2 anti-Nectin-4 ADCs with same payload in same line. The real-world data coming will be GOLD 📊 🔬 Basal-squamous UC = lower HER2/NECTIN4, higher EGFR → less favorable on EVP/DVP → making the Iza-Bren program potentially crucial for this subgroup! We MUST build rational, biomarker-driven sequencing strategies not only availability-driven ones! 💊 What’s your opinion on that topic ? @Dr_Aggen @MichalSternsch @DrRosenbergMSK @jonchou05 @PGrivasMDPhD @drenriquegrande @Markuseckstein3 @braegelmannlab @ViktorGruenwald @merck_de @OncoAlert @weoncologists @PTarantinoMD @DrChoueiri @Uromigos @PowlesTom @DrYukselUrun @nachoduranm @montypal @shilpaonc @apolo_andrea @urotoday @niklas_kluemper @PHilbertMD @pernasales @EvanYRosen @DrDjWatson @yao_zhu_sh @AndreaNecchi #BladderCancer #UroOncology #UBC #ADC #Nectin4 #HER2 #Avelumab #JAVELIN #EV #PrecisionMedicine #Biomarkers #Urology #Oncology #BasalSquamous #SequencingStrategy

European Urology Oncology avatar
⟳ Francesco Claps retweeted
European Urology Oncology@EurUrolOncol·Apr 20

Design and Rationale of the ROGUE-1 Registry: A Multicentric Prospective Registry for Primary T1 Nonmuscle-invasive Bladder Cancer by David D'Andrea et al on behalf of the ROGUE-1 Investigators Read the full article: buff.ly/a4L34IS We thank the authors for choosing EUO to publish your work! @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Post attachment
European Urology Oncology avatar
⟳ Francesco Claps retweeted
European Urology Oncology@EurUrolOncol·Apr 7

Priority Article in EUO today: An Editorial Immunotherapy Escalation in BCG-Naïve NMIBC: Time for Selectivity, Not Enthusiasm by Marco Moschini, Maria Carmen Mir, Jonathan Aning, and Alessandro Volpe on behalf of EAU Oncology Section Read the full article: buff.ly/U6qXTYb We thank the authors for their work! @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Post attachment
European Urology Oncology avatar
⟳ Francesco Claps retweeted
European Urology Oncology@EurUrolOncol·Mar 9

Diagnostic Value of Fluorine-18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Staging Histological Subtypes of Invasive Bladder Cancer by Renee A.G. Lijnen et al Read the article: buff.ly/wjGnWUU We thank the authors for trusting #EUO with your work. @LAUrology_NL @TBoellaard @FraClaps @uroweb @mroupret @GPloussard @jteoh_hk @Ric_Campi @CaPsurvivorship @UroDocAsh @LauraMarandino @RenuEapen @Ecastromarcos @OncoAlert @Sciencedirect

Post attachment
NEJM avatar
⟳ Francesco Claps retweeted
NEJM@NEJM·Feb 19

Original Article: Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer (phase 3 KEYNOTE-905/EV-303 trial) nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T #Oncology

Post attachmentPost attachment
Savio Domenico Pandolfo avatar
⟳ Francesco Claps retweeted
Savio Domenico Pandolfo@PandolfoSD·Feb 13

Honored to announce the second edition of SYNERGY. Save the date!

SYNERGY 2026 – Second Edition Save the Date: 🗓️ May 28–29, 2026 📍 Naples, Italy 👉 This year’s scientific program will focus on locally advanced and oligometastatic GU tumors, in an integrated MDT setting

Post attachmentPost attachment
View quoted post ↗
Karim Touijer avatar
⟳ Francesco Claps retweeted
Karim Touijer@TouijerKarim·Feb 10

in J Urol this month a decision analysis of PLND during RP Take home message: benefits of PLND outweigh risk for most patients. auajournals.org/doi/10.1097/… @VickersBiostats @UrologyMSK #prostatecancer @Uroweb @AmerUrological

Nicola Pavan avatar
⟳ Francesco Claps retweeted
Nicola Pavan@Nicp85Pavan·Jan 22

📣 Corso di Perfezionamento UNIPA: “Diagnostica e Procedure Urologiche Guidate da Imaging” 🗓️ Marzo–Novembre 2026 | 400 ore | 16 CFU Focus su imaging in urologia (eco, TC, RM mp, PET/CT) + procedure guidate. ⏳ Scadenza: 03/02/2026 Info: dipartimento.meprecc@unipa.it

Francesco Claps avatar
Francesco Claps@FraClaps·31 Dec 2025

📬We are pleased to share our comment on @JAMA_current Prostatitis continues to represent diagnostic and therapeutic challenges. We discuss key aspects of prostatitis, with particular emphasis on the role of imaging in prostatic abscess' evaluation 👇 jamanetwork.com/journals/jam…